 |
|
Response, Partial Response, and Nonresponse in Primary Care Treatment of Depression
Patricia K. Corey-Lisle, PhD, RN-CSP;
Rowena Nash, BA, BS;
Paul Stang, PhD;
Ralph Swindle, PhD
Arch Intern Med. 2004;164:1197-1204.
Background Depressive disorders are one of the most common reasons for visits to primary care physicians. This study identifies factors related to poor response to depression treatment with selective serotonin reuptake inhibitors (SSRIs) in primary care settings by (1) examining clinical response taking into account treatment, (2) comparing baseline characteristics and outcomes between patients classified by response, and (3) examining characteristics predicting poor response.
Methods A Randomized Trial Investigating SSRI Treatment (ARTIST) was a prospective naturalistic trial comparing effectiveness of SSRI therapy. Eligible patients were randomized to treatment (N = 601) and followed up for 9 months. Treatment patterns were classified as "adequate" (6-month continuous medication), "aggressive" (defined by a treatment algorithm), or "inadequate" (discontinuations) by patient-reported medication use. Clinical response was determined by use of the Symptom Checklist–20 (SCL-20), with patients classified as remitters (score  6), partial remitters (50% decrease in symptoms), or nonresponders. Groups were compared on baseline characteristics, functioning, and treatment patterns. Multinomial logistic regression was used to determine predictors of response.
Results Of patients completing 6-month evaluations (n = 482), 46% were classified as nonresponders. Additionally, 53% (n = 256) received adequate therapy but did not achieve remission and 13% (n = 61) had aggressive therapy associated with treatment resistance. Significant predictors of nonresponse included older age, diagnosis, worse physical functioning, and lower energy level.
Conclusions A substantial number of adequately treated patients did not respond to antidepressant therapy. Some of these patients may be considered undertreated or treatment-resistant according to current treatment guidelines recommending dose increases or medication switches for less than adequate clinical response.
From Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Ind (Drs Corey-Lisle and Swindle); Department of Psychology, Indiana University, Bloomington (Dr Swindle); Department of Pharmacy, Florida A & M University, Tallahassee (Ms Nash); and Primary Care Network and Galt Associates, Inc, Blue Bell, Pa (Dr Stang). Dr Corey-Lisle is now with Bristol-Myers Squibb, Wallingford, Conn. Drs Corey-Lisle and Swindle are employees and stockholders of Eli Lilly & Company; Ms Nash was an intern for and holds stock in Eli Lilly & Company; and Dr Stang has been a paid consultant for Eli Lilly & Company.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A 60-Year-Old Woman Who Has Felt Sad for Much of Her Life
Salzman
JAMA 2006;295:318-323.
FULL TEXT
Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor
Westanmo et al.
Am J Health Syst Pharm 2005;62:2481-2490.
ABSTRACT
| FULL TEXT
SSRI Response in Routine Primary-Care Depression Treatment
JWatch Psychiatry 2004;2004:6-6.
FULL TEXT
|
